These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30200666)

  • 1. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship.
    Weniger M; Honselmann KC; Liss AS
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies.
    Perez VM; Kearney JF; Yeh JJ
    Front Oncol; 2021; 11():751311. PubMed ID: 34692532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options.
    Ferrara B; Pignatelli C; Cossutta M; Citro A; Courty J; Piemonti L
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC.
    Wang D; Li Y; Ge H; Ghadban T; Reeh M; Güngör C
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits.
    Maneshi P; Mason J; Dongre M; Öhlund D
    Front Cell Dev Biol; 2021; 9():787485. PubMed ID: 34901028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma.
    Sato N; Cheng XB; Kohi S; Koga A; Hirata K
    Acta Pharm Sin B; 2016 Mar; 6(2):101-5. PubMed ID: 27006892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma.
    Kudo D; Suto A; Hakamada K
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma.
    Lee DU; Han BS; Jung KH; Hong SS
    Biomol Ther (Seoul); 2024 May; 32(3):281-290. PubMed ID: 38590092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an in vitro 3D PDAC stroma rich spheroid model.
    Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
    Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition.
    Cannone S; Greco MR; Carvalho TMA; Guizouarn H; Soriani O; Di Molfetta D; Tomasini R; Zeeberg K; Reshkin SJ; Cardone RA
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Role of Desmoplastic Physical Stroma in Pancreatic Cancer Progression Using a Three-Dimensional Collagen Matrix Model.
    Song X; Nihashi Y; Yamamoto M; Setoyama D; Kunisaki Y; Kida YS
    Bioengineering (Basel); 2023 Dec; 10(12):. PubMed ID: 38136028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer.
    Brancato V; Comunanza V; Imparato G; Corà D; Urciuolo F; Noghero A; Bussolino F; Netti PA
    Acta Biomater; 2017 Feb; 49():152-166. PubMed ID: 27916739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Inoculation of 3D Pancreatic Cancer Spheroids Results in Development of Reproducible Stroma-Rich Tumors.
    Durymanov M; Kroll C; Permyakova A; O'Neill E; Sulaiman R; Person M; Reineke J
    Transl Oncol; 2019 Jan; 12(1):180-189. PubMed ID: 30554606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
    Jiang B; Zhou L; Lu J; Wang Y; Liu C; You L; Guo J
    Front Oncol; 2020; 10():576399. PubMed ID: 33178608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
    Oron Y
    Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor⁻Stroma Cross-Talk in Human Pancreatic Ductal Adenocarcinoma: A Focus on the Effect of the Extracellular Matrix on Tumor Cell Phenotype and Invasive Potential.
    Procacci P; Moscheni C; Sartori P; Sommariva M; Gagliano N
    Cells; 2018 Oct; 7(10):. PubMed ID: 30301152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal SPOCK1 supports invasive pancreatic cancer growth.
    Veenstra VL; Damhofer H; Waasdorp C; Steins A; Kocher HM; Medema JP; van Laarhoven HW; Bijlsma MF
    Mol Oncol; 2017 Aug; 11(8):1050-1064. PubMed ID: 28486750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.
    Hartmann N; Giese NA; Giese T; Poschke I; Offringa R; Werner J; Ryschich E
    Clin Cancer Res; 2014 Jul; 20(13):3422-33. PubMed ID: 24763614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery.
    Bhaw-Luximon A; Jhurry D
    Cancer Lett; 2015 Dec; 369(2):266-73. PubMed ID: 26415628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
    Young K; Hughes DJ; Cunningham D; Starling N
    Ther Adv Med Oncol; 2018; 10():1758835918816281. PubMed ID: 30574212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.